🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

951 results for “Eli” Clear

  1. PD-L1/IDO Peptide Vaccine

    IO Biotech

    High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

    phase 1 mab active

    1 trial

  2. PHARMACOKINETICS OF PETRELINTIDE FOLLOWING ADMINISTRATION TO PARTICIPANTS WITH IMPAIRED HEPATIC FUNCTION

    Zealand Pharma A/S

    Healthy / hepatic impaired volunteers only study to assess PK parameters

    phase 1 other active

    1 trial

  3. PTG-100

    Protagonist Therapeutics, Inc

    Celiac Disease

    phase 1 small molecule completed

    1 trial

  4. Palbociclib + Taselisib / Pictilisib

    United Therapeutics Europe Ltd

    Advanced Solid Tumours

    phase 1 small molecule completed

    1 trial

  5. Pembrolizumab plus autologous dendritic cell vaccine in patients with advanced mesothelioma who have failed prior therapies

    Istituto Gentili S.r.l.

    Mesothelioma

    phase 1 other active

    1 trial

  6. Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations.

    Eli Lilly Co.

    Advanced Hematologic Malignancies

    phase 1 other active

    1 trial

  7. Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer

    Janssen-Cilag International N.V.

    Localized Bladder Cancer

    phase 1 other active

    1 trial

  8. Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.

    Novartis Pharmaceuticals

    Locally advanced or metastatic unresectable colorectal cancer (CRC), Locally advanced unresectable or metastatic breast cancer (BC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC)

    phase 1 other active

    1 trial

  9. Phase I study of IAG933 in patients with advanced Mesothelioma and other solid tumors

    Novartis Pharmaceuticals

    Advanced mesothelioma or other solid tumors harboring certain molecular alterations in the Hippo pathway

    phase 1 other active

    1 trial

  10. Poliorix

    GlaxoSmithKline

    Poliomyelitis

    phase 1 mab completed

    1 trial

  11. Pozelimab

    Regeneron UK Limited

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  12. Pozelimab

    Alnylam Netherlands B.V.

    Healthy

    phase 1 small molecule completed

    1 trial

  13. Pozelimab

    Regeneron UK Limited

    Healthy

    phase 1 small molecule completed

    1 trial

  14. Pozelimab

    Regeneron UK Limited

    Geographic Atrophy (GA)

    phase 1 small molecule active

    1 trial

  15. Pozelimab/Cemdisiran

    Regeneron UK Limited

    Sporadic Inclusion Body Myositis (sIBM)

    phase 1 other active

    1 trial

  16. QR-504a

    ProQR Therapeutics N.V.

    Fuchs Endothelial Corneal Dystrophy

    phase 1 small molecule terminated

    1 trial

  17. QT-019C

    Tianjin Huanhu Hospital

    Neuromyelitis Optica Spectrum Disorders

    phase 1 small molecule active

    1 trial

  18. Selinexor

    Karyopharm Therapeutics Inc

    Colorectal Neoplasm

    phase 1 small molecule terminated

    1 trial

  19. Selinexor

    Karyopharm Therapeutics Inc

    Solid Tumor

    phase 1 small molecule completed

    1 trial

  20. Selinexor

    Karyopharm Therapeutics Inc

    Liposarcoma

    phase 1 small molecule terminated

    1 trial

  21. Selinexor

    Karyopharm Therapeutics Inc

    Amyloid

    phase 1 small molecule terminated

    1 trial

  22. Selinexor

    Karyopharm Therapeutics Inc

    Prolymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

  23. Selinexor

    Karyopharm Therapeutics Inc

    Refractory Multiple Myeloma

    phase 1 small molecule active

    1 trial

  24. Selinexor

    Karyopharm Therapeutics Inc

    Soft Tissue Sarcoma

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources